Asia Pacific Newborn Screening Market, by Products (Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals, Maternity & Specialty Clinics, and Diagnostic Centers) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
- Report code : CMI22546 |
- Industry :
Clinical Diagnostic
- Published On : Mar 2019 |
- Pages : 193 Pages |
- Format :
Asia Pacific Newborn Screening Market Insights
Infants are most vulnerable to diseases such as polio, epilepsy, encephaliphitis, asthma, COPD and other respiratory disease, diarrhea, leukemia, anemia, and other rare diseases that results in substantial economic burden.
Newborn screening describes various tests that are performed during first few hours or days of an infant’s life. These tests have the potential of preventing severe health problems and prevents from death. According to American Academy of Pediatrics: 2018, newborn screening and diagnosis are important to ensure that all babies who are deaf or hard of hearing are identified as soon as possible. According to same source, 1 to 3 out of every 1,000 babies born in the U.S. have hearing level outside the typical range. When these babies receive early intervention services, it makes a big difference in their communication and language development in the future.
Asia Pacific newborn screening market size was valued at US$ 171.3 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period (2018 – 2026).
Figure 1. Asia Pacific Newborn Screening Market Value (US$ Mn) Analysis and Forecast and Absolute $ Opportunity
Source: Coherent Market Insights Analysis (2018)
Increasing government initiatives is expected to drive growth of the Asia Pacific newborn screening market
Increasing engagement programs by various government healthcare regulatory bodies for newborn screening and its deployment for wider population base are expected to drive growth of the market during the forecast period. For instance, in June 2014, PerkinElmer, a company engaged in the diagnostics, life science research, food, environmental and industrial testing area, entered into an exclusive collaboration with China's National Health and Family Planning Commission (NHFPC) to implement a three-year training program for newborn screening.
The National Maternal & Children Health Surveillance Office (NMCHSO) is working with PerkinElmer, to increase availability and adoption of newborn screening in China, particularly via expansion in more rural areas.
Moreover, technological advancements in tandem mass spectrometry, colorimetric analysis test, fluorescence analysis test, enzyme or liquid chromatography, and various immunological assays and other analysis and high adoption rate of newborn screening with new technology are factors that are expected to drive growth of the market. In October 2018, LifeCell International, India’s leading stem cell bank and mother & baby diagnostics company, launched RightStart, the world’s first Integrated DNA testing for newborn screening to detect over 50 medical conditions.
However, lack of improvement in healthcare infrastructure and trained professionals is a major factor hindering growth of the Asia Pacific newborn screening market. Newborn screening is still not widely adopted in Asia Pacific region and requires more development and awareness. Countries in Asia Pacific region have high population and less number of trained professionals. High population with low and middle-income level and poor quality health services are hindering growth of the market.
Asia Pacific Newborn Screening Market- Country Analysis
On the basis of country, Asia Pacific newborn screening market is segmented into China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific.
China holds the major share due to innovative and new initiatives by government for implementing various newborn screening programs. Currently Congenital Hypothyroidism (CH) and Phenylketonuria (PKU) and hearing loss are included as national wide screening program in China, which is also mandatory for all newborn.
In addition to this, more than 150 Newborn Screening (NBS) labs in China offer screening program for Congenital Adrenal Hyperplasia (CAH) and Glucose-6-Phosphate Dehydrogenase Deficiency (G-6-PDD), and about 11 million babies had been screened for CAH and G6PD in 2017.
India is expected to witness significant growth in the Asia Pacific newborn screening market, owing to high birth rate in this region. For instance, according to the World Health Organization (WHO) 2016, India’s total population was 1,324,171,000, which is second-largest in Asian countries after China. Newborn birth rate in India is around 34 births per second and 2,062 births per hour.
Figure 2: Asia Pacific Newborn Screening Market Share (%), By Country
Source: Coherent Market Insights Analysis (2018)
Asia Pacific Newborn Screening Market- Competitive Landscape
Key players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.
Newborn screening has evolved from a simple urine or blood screening test to a more comprehensive and complex screening system capable of detecting over 50 different conditions. Newborn screening tests measure a number of markers in infant’s blood that can be either decreased or increased if an infant has certain diseases. Currently, conditions such as cystic fibrosis (CF), congenital hypothyroidism, phenylketonuria (PKU), and around 22 other metabolic conditions that affect protein or fat metabolism can be diagnosed through newborn screening tests.
Market Dynamics
Demand for newborn screening is increasing in order to tackle various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis. According to the World Health Organization (WHO) 2018, globally, around 86% of infants are vaccinated against 26 diseases, however, 19.5 million infants are unvaccinated resulting in death of 2-3 million children every year.
Screening of newborn is rapidly gaining traction in Asia Pacific region, owing to highest birth rate in the region, which is almost half of the global population. Therefore, countries in Asia Pacific are focusing on arranging various workshops to discuss and find solutions for increasing incidence of neonatal diseases. For instance, from March 30–April 1, 2008, PerkinElmer, Inc. arranged a workshop on consolidating newborn screening efforts in Cebu, Philippines, in Asia Pacific region. From June 4-5 in 2010, PerkinElmer, Inc. arranged another workshop in Manila, Philippines, which included workshop participants such as service providers, policy-makers, consumer advocates, and researchers from 11 different countries.
Key features of the study:
- This report provides in-depth analysis of the Asia Pacific newborn screening market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the Asia Pacific newborn screening market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The Asia Pacific newborn screening market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for Asia Pacific newborn screening market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Asia Pacific Newborn Screening Market, By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- Asia Pacific Newborn Screening Market, By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- Asia Pacific Newborn Screening Market, By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- Asia Pacific Newborn Screening Market, By Region:
- China
- By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- By Product Type:
- India
- By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- By Product Type:
- Japan
- By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- By Product Type:
- Australia
- By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- By Product Type:
- South Korea
- By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- By Product Type:
- ASEAN
- By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- By Product Type:
- Rest of Asia Pacific
- By Product Type:
- Hearing Screening Devices
- Mass Spectrometer
- Pulse Oximetry
- Assay Kits and Reagents
- By Test Type:
- Phenylketonuria (PKU)
- Critical Congenital Heart Defect (CCHD)
- Hearing Screening
- Sickle Cell Disease
- Maple Syrup Urine Disease (MSUD)
- Thyroid Disorder
- Biotinidase Deficiency (BTD)
- Others
- By End User:
- Hospitals
- Maternity & Specialty Clinics
- Diagnostic Centers
- By Product Type:
- China
- Company Profiles
- Medtronic plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bio-rad Laboratories, Inc.
- GE Healthcare
- PerkinElmer, Inc.
- Waters Technologies Corporation
- Masimo Corporation
- Natus Medical Inc.
- Trivitron Healthcare Pvt. Ltd.
- ZenTech S.A.
- Agilent Technologies, Inc.
- Danaher Corporation (AB SCIEX)
- Medtronic plc*
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Test Type
- Market Snippet, By End User
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Merger and Acquisition
- Technology Advancements
- Product Launches
- Government Initiatives
- Epidemiology
- Product Recalls
- Regulatory Scenario
- PORTER’S Five Forces
- PEST Analysis
- Asia Pacific Newborn Screening Market, By Product Type, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Hearing Screening Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Mass Spectrometer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Pulse Oximetry
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Assay Kits and Reagents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Asia Pacific Newborn Screening Market, By Test Type, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Phenylketonuria (PKU)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Critical Congenital Heart Defect (CCHD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Hearing Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Maple Syrup Urine Disease (MSUD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Thyroid Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Biotinidase Deficiency (BTD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Asia Pacific Newborn Screening Market, By End User, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Maternity & Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Asia Pacific Newborn Screening Market, By Region, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2026
- Regional Trends
- China
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Test Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2026, (US$ Million)
- India
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Test Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2026, (US$ Million)
- Japan
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Test Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2026, (US$ Million)
- Australia
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Test Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2026, (US$ Million)
- South Korea
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Test Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2026, (US$ Million)
- ASEAN
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Test Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2026, (US$ Million)
- Rest of Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Test Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2026, (US$ Million)
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Medtronic plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bio-rad Laboratories, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GE Healthcare
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- PerkinElmer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Waters Technologies Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Masimo Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Natus Medical Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Trivitron Healthcare Pvt. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ZenTech S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Agilent Technologies, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Danaher Corporation (AB SCIEX)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 32 market data tables and 40 figures on “Newborn Screening Market” - Asia Pacific forecast to 2026”.
Related Insights :
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.